Mild Cognitive Impairment
Conditions
Brief summary
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
Interventions
OTHERPhosphatidylserine
OTHERPlacebo
Sponsors
Enzymotec
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Age greater than or equal to 65 and less than or equal to 85 years. 2. Formal education greater than or equal to 10 years. 3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) 3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) as defined by Peterson, according to The following: 3.1 Clinical Dementia Rating Scale total score (CDR) ≤0.5, and score of each one of the six categories (box scores) ≤ 1. 3.2 Mini Mental State Exam \> 24 3.3 Verbal Paired-Associated Learning test score according to the following ages: Ages 65-70 less than or equal to 18 Ages 71-85\* less than or equal to 17 \*Eligibility of subjects aged between 70 and 71 (i.e., 70.1) will be evaluated according to 71-85 age group score. 4. Adequate vision, hearing, and literacy ability to allow for neuropsychological testing. 5. Able and willing to perform all study procedures. 6. Ability to provide written consent signed by the subject
Exclusion criteria
1. Any significant neurological condition or disorder (e.g., seizure disorder, epilepsy, brain tumors, stroke, etc.) that could cause cognitive deterioration other than suspected MCI. 2. Any medical condition or disorder that could produce cognitive deterioration (i.e., renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances) unless well controlled for at least 3 months. 3. Clinically significant abnormal serum TSH and/or B-12 and/or folic acid levels below the normal range. 4. History of any infective or inflammatory brain disease including viral, fungal or syphilitic etiologies. 5. Head trauma or injury immediately preceding cognitive deterioration, unless over 2 years have passed since full cognitive and functional recovery. 6. Depression at screening as assessed by Geriatric Depression Scale-short version (score ≥5) 7. Current suicidality at screening by Columbia Suicidality Severity Rating Scale. 8. Dementia by DSM-IV criteria. 9. Concomitant use of medications with potent psychotropic properties (e.g. antipsychotics, ADHD treatments, lithium carbonate, anti-epileptic drugs such as Gabapentin). Sedating antihistamines are allowed if administered last dose is administered at least 12 hours before cognitive testing. Usage of prescription or nonprescription antidepressant agents, lipid lowering medications, and anti-hypertensive medications with a stable dosage for more than 2 months prior study entry is permitted. 10. Concomitant use of any medications approved for the symptomatic treatment of dementia due to AD (e.g., NMDA, acetyl choline esterase inhibitors) 11. Use within 3 weeks prior to study entry of any medications with any anti-cholinergic effect (e.g. Atropine, Scopolamine, Tolterodine, Hyoscyamine, Biperiden, Benzatropine, Trihexyphenidyl, Oxybutynin). 12. Use within 4 weeks prior to the study entry of dietary supplements containing DHA, EPA, Phosphatidylserine, Phosphatidylcholine (e.g. Krill oil, Lecithin), or alpha-glycerphosphocholine (GPC). 13. Use within 4 weeks prior to the study entry of medical foods indicated for cognitive or memory impairment \[e.g. Axona, Cerefolin, CerefolinNAC, Souvenaid\]. 14. Concomitant use of any supplements containing ingredients with nootropic or vasodilator properties (e.g., Ginkgo Biloba, Vinpocetine, Piracetam, high energy supplements). 15. Use of an investigational drug within the last 30 days. 16. Allergic reaction or sensitivity to marine products (fish/seafood) and/or soy. 17. Any known condition which in the opinion of the investigator may be possibly causing cognitive impairment other than AD (mania, alcohol or substance abuse, mental retardation, bipolar disorder, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, psychotic disorder, major psychiatric disorder preceding dementia onset or affecting brain function, major surgery ) and/or limits the successful trial completion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in change in the Selective Reminding Test (SRT) between the study groups. | baseline, 3, 6,12 months |
Secondary
| Measure | Time frame |
|---|---|
| Computerized Neurological battery test (NBT) | baseline, 6, 12 and 24 months |
| Mini Mental State Examination (MMSE) | baseline, 12 and 24 months |
| Transition rate to dementia according to DSM-4 criteria | baseline, 3, 6, 12, 18 and 24 months |
| Hamilton Anxiety Rating Scale (HAM-A). | baseline, 12 and 24 months |
| Selective Reminding Test (SRT) | 18 and 24 months |
| Mini Sleep Questionnaire (MSQ) | baseline, 12 and 24 months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety of phosphatidylserine versus placebo treatment | baseline, 3, 6, 12, 18 and 24 months | Clinical laboratory safety data will be collected at baseline and 24 months. Vital signs will be measured at baseline, 12 and 24 months. Adverse events (including changes to concomitant medications) will be documented at all study visits (i.e baseline, 3, 6, 12, 18 and 24 months). |
Countries
Israel, United States
Outcome results
None listed